Objective: Lung cancers are malignant neoplasms arising from lung tissues, with Non-Small Cell Lung Cancer (NSCLC) being the prevalent subtype. miRNA-155 is markedly upregulated in lung cancer cases, facilitating tumor progression. In contrast, findings regarding miRNA-339 levels in lung cancer are inconsistent. In our study, we sought to analyze the serum expression levels of miRNA-155-5p and miRNA-339-3p in patients diagnosed with NSCLC and healthy controls.

Material and Method: miRNAs obtained from serum samples were converted into cDNA. miRNA-339-3p and miRNA-155-5p expression analyses were performed using SYBR GREEN kit.

Results: In the patient group, serum levels of miRNA 339-3p were found to be reduced compared to those in the control group, whereas miRNA 155-5p levels were significantly higher in the patient group than in the controls.

Conclusion: The serum levels of miRNA-155-5p and miRNA-339-3p, which showed significant statistical differences between the patient group and control groups, suggest that these miRNAs may serve as potential biomarkers for the diagnosis of NSCLC.